GPR37L1 mutation associated with a novel neurological disorder
GPR37L1 突变与新型神经系统疾病相关
基本信息
- 批准号:8871619
- 负责人:
- 金额:$ 19.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-06-01 至 2017-05-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAgonistAllelesAmino AcidsAsparagineAstrocytesBiological AssayBiologyCalciumCell membraneCessation of lifeChildCoupledCouplingCyclic AMPDiseaseEnvironmentEvolutionExhibitsExonsFamilyFamily memberG-Protein-Coupled ReceptorsGTP-Binding ProteinsGene MutationGenerationsGenesGenetic studyHeadacheHereditary DiseaseHumanInborn Genetic DiseasesInduced MutationInheritedKnock-outKnockout MiceLaboratoriesLightLysineMediatingMembrane Protein TrafficMissense MutationMusMutateMutationNerve DegenerationNeuraxisNeuronsOligodendrogliaOxidative StressParentsPathologyPathway interactionsPatientsPatternPhenotypePlayPopulationProductionPropertyProteinsPubertyReagentRegulationRelative (related person)RoleSeizuresSignal TransductionSingle Nucleotide PolymorphismSolidStagingStrokeTeenagersTestingToxic effectTransfectionUbiquitinationUntranslated RNAVariantconsanguineous familycytotoxicexomegain of functionhuman diseasein vivoinsightnervous system disorderneuropathologynovelprotein foldingprotein functionpublic health relevancereceptorrhotrafficking
项目摘要
DESCRIPTION (provided by applicant): GPR37L1 is a G protein-coupled receptor that is expressed almost exclusively in the central nervous system. This receptor is highly expressed in astrocytes as well as in oligodendrocytes and certain neuronal populations, and my laboratory recently identified GPR37L1 as a receptor for the secreted neuroprotective and glioprotective factor prosaposin. A GPR37L1 mutation was recently found to be associated with a novel inherited neurological disorder characterized by headaches and seizures starting at the onset of puberty, with the seizures growing more frequent and severe throughout the teen years and ultimately resulting in death by the late teens. The GPR37L1 mutation identified in the affected members of this family is a missense mutation that changes an amino acid in the receptor's third cytoplasmic loop, a region of most G protein-coupled receptors that is important for controlling their signaling and regulation. We will assess the effects of the mutation on the folding, trafficking and signaling of GPR37L1 in order to determine how this mutation might be causing human disease and how patients harboring this mutation might be treated. In addition to providing insights into the neurological disorder associated with the GPR37L1 mutation, these studies will also shed significant light on the normal function of GPR37L1 and thereby set the stage for targeting this receptor pharmacologically in order to generally benefit patients sufferin from stroke and/or other neurodegenerative conditions.
描述(由申请人提供):GPR37L1是一种G蛋白偶联受体,几乎仅在中枢神经系统中表达。这种受体在星形胶质细胞、少突胶质细胞和某些神经元群中高度表达,我的实验室最近发现 GPR37L1 是分泌的神经保护和神经胶质保护因子 prosaposin 的受体。最近发现 GPR37L1 突变与一种新型遗传性神经系统疾病有关,其特征是从青春期开始出现头痛和癫痫发作,癫痫发作在整个青少年时期变得更加频繁和严重,最终导致青少年死亡。在该家族受影响成员中发现的 GPR37L1 突变是一种错义突变,它改变了受体第三细胞质环中的氨基酸,该区域是大多数 G 蛋白偶联受体的区域,对于控制其信号传导和调节非常重要。我们将评估该突变对 GPR37L1 折叠、运输和信号传导的影响,以确定该突变如何导致人类疾病以及如何治疗携带该突变的患者。除了深入了解与 GPR37L1 突变相关的神经系统疾病外,这些研究还将揭示 GPR37L1 的正常功能,从而为药理学靶向该受体奠定基础,从而普遍造福患有中风和/或其他神经退行性疾病的患者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Randy A. Hall其他文献
PDZ interactions between PHLPP phosphatases and the NHERF scaffold
PHLPP 磷酸酶和 NHERF 支架之间的 PDZ 相互作用
- DOI:
- 发表时间:
2012 - 期刊:
- 影响因子:0
- 作者:
M. Kunkel;E. Garcia;Randy A. Hall;A. Newton - 通讯作者:
A. Newton
Secタンパク質膜透過装置の活写にむけて
Sec蛋白膜渗透装置的实时成像
- DOI:
- 发表时间:
2014 - 期刊:
- 影响因子:0
- 作者:
Dan Zhu;Chenchen Li;Andrew M. Swanson;Rosa M. Villalba;Jidong Guo;Zhaobin Zhang;Shannon Matheny;Tatsuro Murakami;Jason R. Stephenson;Sarah Daniel;Masaki Fukata;Randy A. Hall;Jeffrey J. Olson;Gretchen N. Neigh;Yoland Smith;Donald G. Rainnie,;塚崎 智也,春山 隆充 ,菅野 泰功,田中 良樹 ,紺野 宏記 - 通讯作者:
塚崎 智也,春山 隆充 ,菅野 泰功,田中 良樹 ,紺野 宏記
Effects of cyclothiazide on synaptic responses in slices of adult and neonatal rat hippocampus.
环噻嗪对成年和新生大鼠海马切片突触反应的影响。
- DOI:
- 发表时间:
1994 - 期刊:
- 影响因子:1.7
- 作者:
John Larson;To;Randy A. Hall;Gary Lynch - 通讯作者:
Gary Lynch
Mini Review Adhesion G Protein-Coupled Receptors: Signaling, Pharmacology & Mechanisms of Activation
迷你回顾粘附 G 蛋白偶联受体:信号传导、药理学
- DOI:
- 发表时间:
2012 - 期刊:
- 影响因子:0
- 作者:
K. Paavola;Randy A. Hall - 通讯作者:
Randy A. Hall
Mice lacking full length Adgrb1 (Bai1) exhibit social deficitsem,/em increased seizure susceptibility, and altered brain development
缺乏全长 Adgrb1(Bai1)的小鼠表现出社交缺陷、癫痫易感性增加和大脑发育改变。
- DOI:
10.1016/j.expneurol.2022.113994 - 发表时间:
2022-05-01 - 期刊:
- 影响因子:4.200
- 作者:
Fu Hung Shiu;Jennifer C. Wong;Takahiro Yamamoto;Trisha Lala;Ryan H. Purcell;Sharon Owino;Dan Zhu;Erwin G. Van Meir;Randy A. Hall;Andrew Escayg - 通讯作者:
Andrew Escayg
Randy A. Hall的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Randy A. Hall', 18)}}的其他基金
Disease-Associated Mutations and Ligand Activation of the Adhesion G Protein-Coupled Receptor ADGRB2
粘附 G 蛋白偶联受体 ADGRB2 的疾病相关突变和配体激活
- 批准号:
10811019 - 财政年份:2023
- 资助金额:
$ 19.5万 - 项目类别:
Control of Seizure and Migraine Susceptibility by GPR37L1
GPR37L1 控制癫痫和偏头痛易感性
- 批准号:
10449353 - 财政年份:2021
- 资助金额:
$ 19.5万 - 项目类别:
Control of Seizure and Migraine Susceptibility by GPR37L1
GPR37L1 控制癫痫和偏头痛易感性
- 批准号:
10279634 - 财政年份:2021
- 资助金额:
$ 19.5万 - 项目类别:
Control of Seizure and Migraine Susceptibility by GPR37L1
GPR37L1 控制癫痫和偏头痛易感性
- 批准号:
10651823 - 财政年份:2021
- 资助金额:
$ 19.5万 - 项目类别:
Activation and Regulation of the Synaptic Receptor BAI1
突触受体 BAI1 的激活和调节
- 批准号:
9900070 - 财政年份:2019
- 资助金额:
$ 19.5万 - 项目类别:
BAI2 mutation associated with a novel neurological disorder
BAI2 突变与新型神经系统疾病相关
- 批准号:
8877775 - 财政年份:2015
- 资助金额:
$ 19.5万 - 项目类别:
GPR37 & GPR37L1 signaling pathways promoting cell survival: relevance to stroke
探地雷达37
- 批准号:
8753503 - 财政年份:2014
- 资助金额:
$ 19.5万 - 项目类别:
GPR37 & GPR37L1 signaling pathways promoting cell survival: relevance to stroke
探地雷达37
- 批准号:
9464568 - 财政年份:2014
- 资助金额:
$ 19.5万 - 项目类别:
GPR37 & GPR37L1 signaling pathways promoting cell survival: relevance to stroke
探地雷达37
- 批准号:
9117648 - 财政年份:2014
- 资助金额:
$ 19.5万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 19.5万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 19.5万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 19.5万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 19.5万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 19.5万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 19.5万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 19.5万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 19.5万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 19.5万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 19.5万 - 项目类别:














{{item.name}}会员




